11-OH-CBN11-Hydroxycannabinol
Active cannabinol metabolite, CB1 agonist and weak CB2 antagonist in vitro.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₁H₂₆O₃
CAS 30432-08-7
- Family
- Metabolite
- Molar mass
- 326.43 g/mol
Updated on
In plain terms
11-OH-CBN is the form cannabinol takes once the body has transformed it. In the laboratory, it binds CB1 and CB2 receptors much better than cannabinol. It is not sold and remains a research molecule.
Receptors and activity
Target network
- Activates
- Blocks or inhibits
The lower the cited value, the closer the target sits to 11-OH-CBN: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of 11-OH-CBN.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1AgonistKi = 38 nM · rat57 out of 100
Rhee et al. 1997, J Med Chem (new tab) · binding, transfected COS-7 cells; adenylyl cyclase EC50 58.1 nM
- CB2AntagonistKi = 26.6 nM · human60 out of 100
Rhee et al. 1997, J Med Chem (new tab) · binding, transfected COS-7 cells; 20% inhibition of adenylyl cyclase at 10 µM
Pharmacology
11-hydroxycannabinol is the C11-hydroxylated metabolite of cannabinol, described as its major metabolite by Yamamoto et al. (1987). Rhee et al. (1997) measured its affinity for rat CB1 (Ki 38.0 ± 7.2 nM) and human CB2 (Ki 26.6 ± 5.5 nM) expressed in COS-7 cells. It inhibits CB1-coupled adenylyl cyclase with an EC50 of 58.1 nM, but inhibits the CB2 pathway by only 20% at 10 µM: the authors call it a specific, though not potent, CB2 antagonist. In the same study, its dimethylheptyl homologue (11-OH-CBN-DMH) proved a very potent agonist at both receptors, with Ki values of 100 and 200 pM. The cannabinol it derives from is present in cannabis as a degradation product of THC; a single report of 11-hydroxycannabinol in seized marijuana (de A. Leite et al. 2018) has not been confirmed.
Key sources.
- Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L, Breuer A, Mechoulam R. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 1997;40:3228-3233 (new tab)PMID 9379442
- Yamamoto I, Watanabe K, Kuzuoka K, Narimatsu S, Yoshimura H. The pharmacological activity of cannabinol and its major metabolite, 11-hydroxycannabinol. Chem Pharm Bull 1987;35:2144-2147 (new tab)PMID 3664823
- de A Leite J et al. Extraction and isolation of cannabinoids from marijuana seizures and characterization by 1H NMR allied to chemometric tools. Sci Justice 2018;58:355-365 (new tab)PMID 30193661
- Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4:1770-1804 (new tab)PMID 17712819
- ANSM, consolidated list of substances classified as narcotics, updated 16 February 2026 (annex IV, « benzo[c]chromene » clause) (new tab)
- PubChem, 11-Hydroxycannabinol, CID 3082311 (new tab)
History
- Source
- 11-OH-CBN forms in the body by hydroxylation of cannabinol (Yamamoto et al. 1987). Cannabinol itself is present in cannabis as a degradation product of THC. A single report of 11-hydroxycannabinol in seized marijuana samples (de A. Leite et al. 2018, identification by gas chromatography and mass spectrometry) has not been confirmed: its occurrence in the plant remains unestablished.
Metabolic pathway
No established plant pathway. In the body, the C11 methyl of cannabinol is hydroxylated to a primary alcohol, a reaction analogous to the one turning Δ9-THC into 11-OH-THC. The cytochrome P450 isoforms involved in humans were not found in the sources consulted.
Legal framework
- European Union
11-OH-CBN is named in no schedule of the United Nations conventions and in no European Union control measure. Its status falls to each Member State's law. No marketing authorisation concerns it.
- France
11-OH-CBN is not named on the French narcotics list, but its structure meets the generic "benzo[c]chromene" clause of annex IV (ANSM decisions of 22 May and 3 June 2024): ring A not hydrogenated, hydroxyl at position 1, pentyl chain at 3, two methyls at 6 and a hydroxyalkyl group at 9. The clause's exclusion covers only cannabinol (CBN) and cannabinolic acid (CBNA), not their derivatives. No decision has, however, ruled on this molecule by name; it is sold only as a research standard.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Metabolite
- Chemistry
C5 side chain
- Parent molecule
Active metabolite.
- Natural trace reported
11-hydroxycannabinol is reported, by gas chromatography coupled to mass spectrometry, in an HPLC-purified fraction of marijuana samples seized in Brazil (de A. Leite et al. 2018). A single report, on seized and aged material, with no isolation confirmed by another team; unverified.
- Verification
Every fact on this entry was checked against its primary sources on 20 October 2026.
- Wikipedia (English)
11-Hydroxycannabinol (new tab)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L, Breuer A, Mechoulam R. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 1997;40:3228-3233 (new tab)PMID 9379442
- Yamamoto I, Watanabe K, Kuzuoka K, Narimatsu S, Yoshimura H. The pharmacological activity of cannabinol and its major metabolite, 11-hydroxycannabinol. Chem Pharm Bull 1987;35:2144-2147 (new tab)PMID 3664823
- de A Leite J et al. Extraction and isolation of cannabinoids from marijuana seizures and characterization by 1H NMR allied to chemometric tools. Sci Justice 2018;58:355-365 (new tab)PMID 30193661
- Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4:1770-1804 (new tab)PMID 17712819
- ANSM, consolidated list of substances classified as narcotics, updated 16 February 2026 (annex IV, « benzo[c]chromene » clause) (new tab)
- PubChem, 11-Hydroxycannabinol, CID 3082311 (new tab)
Identifiers
Names
- Common name
- 11-Hydroxycannabinol
- IUPAC name
- 9-(hydroxymethyl)-6,6-dimethyl-3-pentylbenzo[c]chromen-1-ol
- Other names
- 11-OH-CBN · 11-hydroxy-CBN
Identifiers
- Formula
- C₂₁H₂₆O₃
- CAS
- 30432-08-7
- PubChem CID
- 3082311(new tab)
- InChIKey
- YDKZOUNVEIGJPO-UHFFFAOYSA-N
- SMILES
- CCCCCC1=
CC(= C2C(= C1) OC(C3= C2C= C(C= C3) CO) (C) C) O
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.